

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Hepatology

**Manuscript NO:** 34220

**Title:** Safety and Efficacy of ledipasvir/sofosbuvir on hepatitis C eradication in HCV/HIV co-infected patients

**Reviewer's code:** 02860745

**Reviewer's country:** Argentina

**Science editor:** Jin-Xin Kong

**Date sent for review:** 2017-04-10

**Date reviewed:** 2017-04-15

| CLASSIFICATION                              | LANGUAGE EVALUATION  | SCIENTIFIC MISCONDUCT                          | CONCLUSION   |
|---|--|--|--|
| <input type="checkbox"/> Grade A: Excellent | <input type="checkbox"/> Grade A: Priority publishing                | Google Search:                                 | <input type="checkbox"/> Accept                        |
| <input type="checkbox"/> Grade B: Very good | <input type="checkbox"/> Grade B: Minor language polishing           | <input type="checkbox"/> The same title        | <input type="checkbox"/> High priority for publication |
| <input type="checkbox"/> Grade C: Good      | <input type="checkbox"/> Grade C: A great deal of language polishing | <input type="checkbox"/> Duplicate publication | <input type="checkbox"/> Rejection                     |
| <input type="checkbox"/> Grade D: Fair      | <input type="checkbox"/> Grade D: Rejected                           | <input type="checkbox"/> Plagiarism            | <input type="checkbox"/> Minor revision                |
| <input type="checkbox"/> Grade E: Poor      |  | <input type="checkbox"/> No                    | <input type="checkbox"/> Major revision                |
|   |  | BPG Search:                                    |  |
|   |  | <input type="checkbox"/> The same title        |  |
|   |  | <input type="checkbox"/> Duplicate publication |  |
|   |  | <input type="checkbox"/> Plagiarism            |  |
|   |  | <input type="checkbox"/> No                    |  |

## COMMENTS TO AUTHORS

Congratulations to authors on this clearly written and stylish manuscript. The approach is not very original (in the last years several papers regarding the efficacy of DDA in real life settings have been published) but since in this subgroup of patients there are few publications, it is still interesting. Some information is missing that would interest the common practitioner: 1. What kind of previous treatments were administered to patients? Peg-IFN? DDA? 2. Were patients with cirrhosis previously exposed to peginterferon treated with ribavirin? If not, why? 3. How many patients used tenofovir? Were tenofovir levels monitored? Guidelines state this control as mandatory when using tenofovir and ledipasvir.... Some information is described in the discussion section, but no specific analysis or hard data is shown regarding this point 4. Occult hbv infections is mentioned as "not observed" in discussion...but this is not shown in results!! What HBV serology was obtained? How was the follow up done? For how long? In summary,



**Baishideng  
Publishing  
Group**

7901 Stoneridge Drive, Suite 501,  
Pleasanton, CA 94588, USA

**Telephone:** +1-925-223-8242

**Fax:** +1-925-223-8243

**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)

<https://www.wjgnet.com>

useful information and well written paper, but basic data need to be further described (at least to match the affirmations made in the discussion section)

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Hepatology

**Manuscript NO:** 34220

**Title:** Safety and Efficacy of ledipasvir/sofosbuvir on hepatitis C eradication in HCV/HIV co-infected patients

**Reviewer's code:** 03269732

**Reviewer's country:** China

**Science editor:** Jin-Xin Kong

**Date sent for review:** 2017-04-10

**Date reviewed:** 2017-04-16

| CLASSIFICATION   | LANGUAGE EVALUATION  | SCIENTIFIC MISCONDUCT                          | CONCLUSION   |
|--|--|--|--|
| <input checked="" type="checkbox"/> Grade A: Excellent | <input checked="" type="checkbox"/> Grade A: Priority publishing     | Google Search:                                 | <input checked="" type="checkbox"/> Accept             |
| <input type="checkbox"/> Grade B: Very good            | <input type="checkbox"/> Grade B: Minor language polishing           | <input type="checkbox"/> The same title        | <input type="checkbox"/> High priority for publication |
| <input type="checkbox"/> Grade C: Good                 | <input type="checkbox"/> Grade C: A great deal of language polishing | <input type="checkbox"/> Duplicate publication | <input type="checkbox"/> Rejection                     |
| <input type="checkbox"/> Grade D: Fair                 | <input type="checkbox"/> Grade D: Rejected                           | <input type="checkbox"/> Plagiarism            | <input type="checkbox"/> Minor revision                |
| <input type="checkbox"/> Grade E: Poor                 |  | <input checked="" type="checkbox"/> No         | <input type="checkbox"/> Major revision                |
|  |  | BPG Search:                                    |  |
|  |  | <input type="checkbox"/> The same title        |  |
|  |  | <input type="checkbox"/> Duplicate publication |  |
|  |  | <input type="checkbox"/> Plagiarism            |  |
|  |  | <input checked="" type="checkbox"/> No         |  |

## COMMENTS TO AUTHORS

The potential drug-drug interactions between direct acting antiviral agents and antiretrovirals are one of the major concerns during the antiviral treatment in the HCV/HIV co-infected patients. This article entitled " Safety and Efficacy of ledipasvir/sofosbuvir on hepatitis C eradication in HCV/ HIV co-infected patients" by Xiaoping He et al. showed that "The oral combination of ledipasvir/sofosbuvir represents a safe and well tolerated HCV treatment option that does not require modification for many of the common HIV ART". Although this is an one-armed, respective study, this paper still provided readers some experiences in HCV/HIV coinfection treatment. Therefore, it is recommended to be published.